A Phase 4 interventional study of Levodopa/carbidopa/entacapone and Levodopa/carbidopa in Parkinson's Disease, sponsored by Novartis. Completed at 26 sites in Spain. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-03-15.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.
Among the 51 studies testing levodopa in Parkinson Disease, this one is the 17th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2006, is one of 17 in phase 4, and was the 13th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 30–80
Emory University · Sites in United States
Ages 45–75 · Healthy volunteers
Beth Israel Deaconess Medical Center · Sites in United States
By country, each count listing its studies:
Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 11 · Phase 3 12 · Phase 4 17
First in 1998; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 56 across the 50 interventional studies. Of the 45 that completed or were terminated, 18 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 51 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
21 studies in Parkinson Disease by Novartis: none open now, none under way, none of them phase 3. Of 20 finished, 5 (25%) have results posted.
Among the 21 studies in Parkinson Disease by Novartis, this one is the 12th largest by enrollment, is the only one that started in 2006, is one of 6 in phase 4, and was the 6th registered.
Novartis’s Parkinson Disease studies by the year they started, since 2002.
1 of the studies testing levodopa in Parkinson Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06234995Emory UniversityCortical Electrophysiology of Response Inhibition in Parkinson's Disease | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing levodopa in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 21 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study evaluated the efficacy of levodopa/carbidopa/entacapone vs levodopa/carbidopa in patients with Parkinson's disease and early wearing-off with levodopa
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must be using any of the following levodopa/carbidopa standard formulation levodopa/carbidopa 100/25mg dose in any intake of the day.
Exclusion Criteria:
The following levodopa/carbidopa doses and strengths are not permitted:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Levodopa/carbidopa/entacapone
Drug: Levodopa/carbidopa
Drug pages: Levodopa · Carbidopa · Entacapone
Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
Drug pages: Levodopa · Carbidopa
Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3
The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part II (items 5-17; total score 0-52, calculated as the sum of the individual items) measures the patient's activities of daily living. A lower total score indicates greater symptom control. A negative change score indicates improvement.
Time frame: Baseline to end of study (Month 3)
Change in the UPDRS Part I (Mentation, Behavior, and Mood) Score From Baseline to Month 3
The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part I (items 1-4; total score 0-16, calculated as the sum of the individual items) measures the patient's mentation, mood and behavior. A lower total score indicates greater symptom control. A negative change score indicates improvement.
Time frame: Baseline to end of study (Month 3)
Change in the UPDRS Part III (Motor Function) Score From Baseline to Month 3
The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part III (items 18-31; total score 0-56, calculated as the sum of the individual items) measures the patient's motor function. A lower total score indicates greater symptom control. A negative change score indicates improvement.
Time frame: Baseline to end of study (Month 3)
Change in the UPDRS Part IV (Complications of Therapy) Score From Baseline to Month 3
Part IV of the UPDRS measures complications the patient may be experiencing with therapy and was only collected at and after the visit at which the first dyskinesia or episode of wearing-off was recorded. Part IV is composed of 3 sections and 11 items: A (32-35, dyskinesia), B (36-39, clinical fluctuations, C (40-42, other complications) (total score 0-23, calculated as the sum of the individual items). A lower total score indicates greater symptom control. A negative change score indicates improvement.
Time frame: Baseline to end of study (Month 3)
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Month 3
The PDQ-39 is an instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognitions, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The total score can range from 39 to 195. A lower score indicates better quality of life. A positive change score indicates an improvement.
Time frame: Baseline to end of study (Month 3)
Patient and Investigator Global Evaluation of the Patient
Both the patient and the investigator made an evaluation of the change in the patient's condition by rating the condition of the patient at the end of the study compared to patient's condition at baseline. The rating was made on a scale ranging from -3 to +3: (-3: Very much improved, -2: much improved, -1: mild improvement, 0: no change, +1: mild deterioration, +2: much deterioration, +3: very much deterioration). A negative score indicates improvement.
Time frame: Baseline to end of study (Month 3)
Change on the QUICK Questionnaire (QQ) Score From Baseline to Month 3
The QQ is a self-administered questionnaire that includes 19 wearing-off (WO) symptoms (motor and non-motor). A positive answer to each of the 19 symptoms is given by patients if they presented with a symptom and the symptom disappeared after the next drug dose. Two positive answers are diagnostic of wearing-off (WO). A negative change score indicates improvement.
Time frame: Baseline to end of study (Month 3)
| Milestone | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| Started | 46 | 49 |
| Completed | 35 | 39 |
| Not completed | 11 | 10 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Other | 8 | 10 |
The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part II (items 5-17; total score 0-52, calculated as the sum of the individual items) measures the patient's activities of daily living. A lower total score indicates greater symptom control. A negative change score indicates improvement.
| Units on a scale | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3 | -2.5 ± 2.8 | -0.5 ± 3.0 |
The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part I (items 1-4; total score 0-16, calculated as the sum of the individual items) measures the patient's mentation, mood and behavior. A lower total score indicates greater symptom control. A negative change score indicates improvement.
| Units on a scale | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| Change in the UPDRS Part I (Mentation, Behavior, and Mood) Score From Baseline to Month 3 | -0.5 ± 1.6 | -0.2 ± 1.0 |
The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part III (items 18-31; total score 0-56, calculated as the sum of the individual items) measures the patient's motor function. A lower total score indicates greater symptom control. A negative change score indicates improvement.
| Units on a scale | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| Change in the UPDRS Part III (Motor Function) Score From Baseline to Month 3 | -4.0 ± 4.6 | -1.42 ± 5.5 |
Part IV of the UPDRS measures complications the patient may be experiencing with therapy and was only collected at and after the visit at which the first dyskinesia or episode of wearing-off was recorded. Part IV is composed of 3 sections and 11 items: A (32-35, dyskinesia), B (36-39, clinical fluctuations, C (40-42, other complications) (total score 0-23, calculated as the sum of the individual items). A lower total score indicates greater symptom control. A negative change score indicates improvement.
| Units on a scale | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| Change in the UPDRS Part IV (Complications of Therapy) Score From Baseline to Month 3 | -0.6 ± 1.8 | -0.1 ± 1.3 |
The PDQ-39 is an instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognitions, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The total score can range from 39 to 195. A lower score indicates better quality of life. A positive change score indicates an improvement.
| Units on a scale | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Month 3 | 6.3 ± 20.4 | 0.8 ± 15.6 |
Both the patient and the investigator made an evaluation of the change in the patient's condition by rating the condition of the patient at the end of the study compared to patient's condition at baseline. The rating was made on a scale ranging from -3 to +3: (-3: Very much improved, -2: much improved, -1: mild improvement, 0: no change, +1: mild deterioration, +2: much deterioration, +3: very much deterioration). A negative score indicates improvement.
| Units on a scale | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| Patient global evaluation | -0.9 ± 1.1 | -0.4 ± 1.2 |
| Investigator global evaluation | -0.9 ± 1.0 | -0.3 ± 0.9 |
The QQ is a self-administered questionnaire that includes 19 wearing-off (WO) symptoms (motor and non-motor). A positive answer to each of the 19 symptoms is given by patients if they presented with a symptom and the symptom disappeared after the next drug dose. Two positive answers are diagnostic of wearing-off (WO). A negative change score indicates improvement.
| Positive answers | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| Change on the QUICK Questionnaire (QQ) Score From Baseline to Month 3 | -0.6 ± 1.8 | -0.6 ± 2.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levodopa/Carbidopa/Entacapone | — | 1/45 (2.2%) | 10/45 (22.2%) |
| Levodopa/Carbidopa | — | 1/49 (2%) | 3/49 (6.1%) |
| Event | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/45 | 0/49 |
| DelusionPsychiatric disorders | 0/45 | 1/49 |
| Event | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa |
|---|---|---|
| DyskinesiaNervous system disorders | 7/45 | 1/49 |
| AnxietyPsychiatric disorders | 5/45 | 0/49 |
| RetchingGastrointestinal disorders | 3/45 | 2/49 |
| Age Continuous(Years) | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa | Total |
|---|---|---|---|
| Mean | 66.40 ± 8.18 | 66.45 ± 9.04 | 66.43 ± 8.59 |
| Sex: Female, Male(Participants) | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa | Total |
|---|---|---|---|
| Female | 25 | 22 | 47 |
| Male | 20 | 27 | 47 |
| Region of Enrollment(participants) | Levodopa/Carbidopa/Entacapone | Levodopa/Carbidopa | Total |
|---|---|---|---|
| Spain | 45 | 49 | 94 |
The record gives a start of Oct 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levodopa · Carbidopa · Entacapone